Daewoong Pharma (069620)
Korea Stock Exchange · Korea · prices in KRW · close of 19 Oct 2026
Key indicators
| Last close | KRW 107,800.00 |
|---|---|
| 52-week range | 101,900.00 – 198,713.20 |
| Return, 1 month / 3 months | −3.0% / −12.0% |
| Return, 1 year / 3 years | −19.3% / +6.3% |
| Trend | Below its 200-day average |
| RSI (14) | 45 |
| Volatility (1 year) | 47.8% |
| Worst drawdown (1 year) | -46.6% |
| Average daily value traded | 2,954.48M KRW |
| Dividend yield | 0.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Daewoong Pharmaceutical is a South Korean pharmaceutical company that develops and makes prescription medicines and over-the-counter remedies. Its products include treatments for digestive complaints, botulinum toxin preparations used in medical and cosmetic care, and a range of other ethical drugs sold to hospitals, clinics and pharmacies. The company is based in Korea and serves patients and healthcare providers through its domestic operations and exports, while also running related healthcare and consumer health activities.
Daewoong Pharma trades under the code 069620 on the Korea Stock Exchange in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Daewoong Pharma (069620) trades on the Korea Stock Exchange in Korea. It last closed at KRW 107,800.00 on 19 October 2026.
Its price-based Market X-Ray is 36 out of 100 (a weak price profile), ranking 719 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 19.3% and over the last three months it fell 12.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 24 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -23.4% | ||
| From 52-week high | -44.4% | ||
| Momentum | 24 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.0% | ||
| 6-month return | -28.3% | ||
| 12-month return, skipping the last month | -16.8% | ||
| Stability (higher is calmer) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 47.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.6% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 2,954.48M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 11 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.6% | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.1% |
|---|---|
| 1 month | −3.0% |
| 3 months | −12.0% |
| 6 months | −28.3% |
| 1 year | −19.3% |
| 3 years | +6.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 116,024.00 / 140,772.17 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 4,004.60 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Dec 2025 | KRW 600.0000 |
| 27 Dec 2024 | KRW 600.0000 |
| 28 Dec 2022 | KRW 600.0000 |
| 29 Dec 2021 | KRW 600.0000 |
| 29 Dec 2020 | KRW 600.0000 |
| 27 Dec 2019 | KRW 600.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.